Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/30/2025

Management of Elevated LDL Cholesterol

Risk Stratification and Treatment Goals

  • The American Heart Association recommends targeting LDL <100 mg/dL for patients without diabetes or cardiovascular disease, and initiating statin therapy at LDL ≥130 mg/dL 2
  • For patients with diabetes but no cardiovascular disease, the American Diabetes Association recommends targeting LDL <100 mg/dL and initiating statin therapy at LDL ≥130 mg/dL, though consideration of treatment for LDL 100-129 mg/dL is advised 3, 4
  • Patients with cardiovascular disease or diabetes plus other risk factors should target LDL <70 mg/dL, and initiate statin therapy regardless of baseline LDL, as recommended by the American College of Cardiology 5, 1
  • The American College of Cardiology also recommends targeting LDL <55 mg/dL for highest-risk patients with clinical cardiovascular disease 1

Lifestyle Modifications

  • The American Heart Association recommends reducing saturated fat to <7% of total calories, as part of an AHA Step II diet pattern 6, 1
  • Dietary cholesterol should be limited to <200 mg/day, according to the American College of Cardiology 1
  • Trans fats should be eliminated completely, as advised by the American Heart Association 1
  • Adding plant stanols/sterols and viscous fiber can enhance cholesterol lowering, as recommended by the American College of Cardiology 1
  • At least 30 minutes of moderate-intensity exercise most days, plus resistance training 2 days/week, is recommended by the American Heart Association 1
  • Smoking cessation is critical for cardiovascular risk reduction, as emphasized by the American Heart Association 6, 1

Pharmacological Therapy

  • High-potency statins (such as atorvastatin, rosuvastatin, or pitavastatin) are the drugs of choice for LDL lowering, as recommended by the American College of Cardiology 3, 4, 1
  • For patients who do not achieve LDL goals with statin monotherapy, adding ezetimibe as second-line therapy is recommended by the American College of Cardiology 1
  • Alternative second-line options include fenofibrate (preferred over gemfibrozil due to lower rhabdomyolysis risk with statins) and bile acid sequestrants (resins), as advised by the American Diabetes Association 4, 5
  • Combination therapy with statin + ezetimibe is considered the safest combination for achieving lower LDL goals, as recommended by the American College of Cardiology 5, 1

Monitoring and Follow-up

  • Lipid panels should be obtained 4-12 weeks after initiating therapy to assess response, as recommended by the American College of Cardiology 1
  • Liver function tests, creatine kinase, glucose, and creatinine should be monitored before starting and periodically thereafter, as advised by the American Heart Association 1
  • Repeat lipid profiles at 4-6 weeks post-hospitalization (if applicable) and 2 months after medication changes, as recommended by the American Heart Association 6